Compare Stocks: CYTK, ALNY, GMAB, and ROIV

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$165.00 -5.2%	$236.49	$163.30 ▼ $479.79	$23.28B	0.28	1.90 million shs	7.05 million shs
CYTK Cytokinetics	$62.99 -0.5%	$67.50	$58.05 ▼ $88.31	$7.88B	0.41	1.75 million shs	1.26 million shs
GMAB Genmab A/S	$57.06 +1.0%	$37.12	$23.62 ▼ $59.97	$35.25B	0.81	6.44 million shs	8.65 million shs
ROIV Roivant Sciences	$36.91 -1.6%	$36.65	$19.30 ▼ $42.50	$27.10B	1.1	6.66 million shs	4.57 million shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	-25.13%	-23.44%	-31.51%	-15.34%	-63.87%
CYTK Cytokinetics	+3.31%	+1.57%	-3.55%	-17.92%	+2.13%
GMAB Genmab A/S	-1.40%	+41.23%	+58.81%	+95.67%	+95.13%
ROIV Roivant Sciences	+1.10%	+0.19%	+2.79%	+10.65%	+100.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$165.00 -5.2%	$236.49	$163.30 ▼ $479.79	$23.28B	0.28	1.90 million shs	7.05 million shs
CYTK Cytokinetics	$62.99 -0.5%	$67.50	$58.05 ▼ $88.31	$7.88B	0.41	1.75 million shs	1.26 million shs
GMAB Genmab A/S	$57.06 +1.0%	$37.12	$23.62 ▼ $59.97	$35.25B	0.81	6.44 million shs	8.65 million shs
ROIV Roivant Sciences	$36.91 -1.6%	$36.65	$19.30 ▼ $42.50	$27.10B	1.1	6.66 million shs	4.57 million shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	-25.13%	-23.44%	-31.51%	-15.34%	-63.87%
CYTK Cytokinetics	+3.31%	+1.57%	-3.55%	-17.92%	+2.13%
GMAB Genmab A/S	-1.40%	+41.23%	+58.81%	+95.67%	+95.13%
ROIV Roivant Sciences	+1.10%	+0.19%	+2.79%	+10.65%	+100.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.70	Moderate Buy	$325.39	97.21% Upside
CYTK Cytokinetics	2.86	Moderate Buy	$105.44	67.40% Upside
GMAB Genmab A/S	2.85	Moderate Buy	$53.61	-6.04% Downside
ROIV Roivant Sciences	2.79	Moderate Buy	$46.55	26.11% Upside

Current Analyst Ratings Breakdown

Latest CYTK, ALNY, GMAB, and ROIV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/30/2026	ALNY Alnylam Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$550.00 ➝ $329.00
10/30/2026	ALNY Alnylam Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$290.00
10/30/2026	ALNY Alnylam Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$460.00 ➝ $287.00
10/30/2026	ALNY Alnylam Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Strong-Buy ➝ Outperform	$420.00 ➝ $315.00
10/30/2026	ALNY Alnylam Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$425.00 ➝ $375.00
10/30/2026	ALNY Alnylam Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Outperform	$350.00 ➝ $320.00
10/30/2026	ALNY Alnylam Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$482.00 ➝ $354.00
10/30/2026	ALNY Alnylam Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Equal Weight	$300.00 ➝ $240.00
10/30/2026	ALNY Alnylam Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$536.00 ➝ $320.00
10/30/2026	ALNY Alnylam Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Equal Weight	$253.00 ➝ $220.00
10/30/2026	GMAB Genmab A/S	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Equal Weight	$42.00 ➝ $57.00

(Data available from 10/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$3.71B	5.94	$2.65 per share	62.23	$5.97 per share	27.64
CYTK Cytokinetics	$67.67M	115.83	N/A	N/A	($5.39) per share	-11.69
GMAB Genmab A/S	$4.13B	8.62	$1.63 per share	35.10	$9.10 per share	6.27
ROIV Roivant Sciences	$8.26M	3,227.70	N/A	N/A	$7.35 per share	5.02

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	$313.75M	$5.38	8.57	17.86	N/A	52.85%	246.94%	50.77%	N/A
CYTK Cytokinetics	-$784.96M	-$7.22	N/A	N/A	N/A	-1,321.12%	N/A	-51.01%	11/4/2026 (Estimated)
GMAB Genmab A/S	$963M	$1.27	44.93	33.76	2.26	19.08%	14.89%	7.73%	11/5/2026 (Estimated)
ROIV Roivant Sciences	-$299.77M	-$0.53	N/A	N/A	N/A	-3,534.96%	-22.94%	-21.53%	11/9/2026 (Estimated)

Latest CYTK, ALNY, GMAB, and ROIV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q2 2027	ROIV Roivant Sciences	-$0.3666	N/A	N/A	N/A	$3.74 million	N/A
11/5/2026	Q3 2026	GMAB Genmab A/S	$0.37	N/A	N/A	N/A	$1.20 billion	N/A
11/4/2026	Q3 2026	CYTK Cytokinetics	-$1.44	N/A	N/A	N/A	$41.20 million	N/A
10/29/2026	Q3 2026	ALNY Alnylam Pharmaceuticals	$1.66	$16.26	+$14.60	$15.72	$1.43 billion	$1.46 billion
8/7/2026	Q1 2027	ROIV Roivant Sciences	-$0.2996	-$0.26	+$0.0396	-$0.26	$2.06 million	$1.44 million
8/6/2026	Q2 2026	CYTK Cytokinetics	-$1.63	-$1.50	+$0.13	-$1.50	$17.59 million	$28.62 million
8/6/2026	Q2 2026	GMAB Genmab A/S	$0.37	$0.54	+$0.17	$0.4910	$1.12 billion	$1.16 billion
7/30/2026	Q2 2026	ALNY Alnylam Pharmaceuticals	$1.63	$1.84	+$0.21	$1.21	$1.32 billion	$1.29 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CYTK Cytokinetics	N/A	N/A	N/A	N/A	N/A
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	0.75	3.05	2.99
CYTK Cytokinetics	N/A	6.66	6.66
GMAB Genmab A/S	0.81	2.46	2.44
ROIV Roivant Sciences	N/A	16.72	16.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
CYTK Cytokinetics	N/A
GMAB Genmab A/S	7.07%
ROIV Roivant Sciences	64.76%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	0.86%
CYTK Cytokinetics	2.60%
GMAB Genmab A/S	1.54%
ROIV Roivant Sciences	8.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,770	133.81 million	132.66 million	Optionable
CYTK Cytokinetics	673	124.43 million	121.20 million	Optionable
GMAB Genmab A/S	3,029	624.06 million	614.45 million	Optionable
ROIV Roivant Sciences	721	722.32 million	658.76 million	Optionable

CYTK, ALNY, GMAB, and ROIV Headlines

Recent News About These Companies

Roivant Sciences (NASDAQ:ROIV) Stock: Insider Eric Venker Sells 200,000 Shares

October 30 at 7:07 PM | marketbeat.com

Roivant Sciences (NASDAQ:ROIV) Stock Price Expected to Rise, Citigroup Analyst Says

October 30 at 1:54 AM | americanbankingnews.com

Roivant Social Ventures Announced Support of No Patient Left Behind with Six-Figure Organizational Legacy Gift

October 29 at 12:36 PM | marketscreener.comM

Roivant Sciences (NASDAQ:ROIV) Share Price Crosses Above 50-Day Moving Average - Here's What Happened

October 29 at 4:59 AM | marketbeat.com

Roivant Sciences (NASDAQ:ROIV) Stock Gets Price Target Increase from Citigroup

October 28 at 4:17 PM | marketbeat.com

Roivant Sciences (NASDAQ:ROIV) & Verastem (NASDAQ:VSTM) Head-To-Head Survey

October 27 at 6:57 AM | americanbankingnews.com

Roivant Sciences Ltd. (ROIV) Discusses Phase 3 Results for Brepocitinib in Non-Infectious Uveitis - Slideshow

October 24, 2026 | seekingalpha.com

Roivant Soars 8% as Brepocitinib Delivers “Phenomenal Results” in Two Phase 3 Uveitis Trials

October 23, 2026 | finance.yahoo.com

Analysts Conflicted on These Healthcare Names: Roivant Sciences (ROIV) and 4D Molecular Therapeutics (FDMT)

October 23, 2026 | theglobeandmail.com

Roivant Sciences (NASDAQ:ROIV) CEO Sells $7,022,000.00 in Stock

October 23, 2026 | insidertrades.com

Roivant Sciences Ltd. $ROIV Shares Newly Purchased by Sumitomo Mitsui DS Asset Management Company Ltd

October 23, 2026 | marketbeat.com

Roivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 200,000 Shares of Company Stock

October 22, 2026 | marketbeat.com

Roivant’s TYK2/JAK inhibitor reduces need for steroids in inflammatory eye disease

October 22, 2026 | biospace.comB

Roivant Sciences Ltd. announces positive results in CLARITY-1 and CLARITY-2 phase 3 trials for brepocitinib

October 22, 2026 | msn.com

Stocks making the biggest moves midday: SpaceX, Meta Platforms, Super Micro Computer, Roivant Sciences & more

October 21, 2026 | cnbc.com

Roivant Sciences Ltd. (ROIV) Discusses Phase 3 Results for Brepocitinib in Non-Infectious Uveitis Transcript

October 21, 2026 | seekingalpha.com

Roivant Sciences’ Brepocitinib Delivers Positive Phase III Uveitis Results

October 21, 2026 | marketbeat.com

Roivant Sciences (NASDAQ:ROIV) Shares Gap Up - Here's What Happened

October 21, 2026 | marketbeat.com

Roivant Sciences Says Brepocitinib Meets Primary Goal In Uveitis Trials; Shares Rise

October 21, 2026 | rttnews.com

Roivant Sciences stock surges on positive uveitis trial data

October 21, 2026 | finance.yahoo.com

Roivant Sciences' Brepocitinib Achieves Primary Endpoint in Two Phase 3 Trials in Non-Infectious Uveitis

October 21, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYTK, ALNY, GMAB, and ROIV Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$165.00 -9.00 (-5.17%)

Closing price 04:00 PM Eastern

Extended Trading

$165.73 +0.73 (+0.44%)

As of 07:58 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Cytokinetics NASDAQ:CYTK

$62.99 -0.32 (-0.51%)

Closing price 04:00 PM Eastern

Extended Trading

$63.50 +0.51 (+0.81%)

As of 07:30 PM Eastern

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Genmab A/S NASDAQ:GMAB

$57.06 +0.57 (+1.01%)

Closing price 04:00 PM Eastern

Extended Trading

$57.08 +0.02 (+0.03%)

As of 07:34 PM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Roivant Sciences NASDAQ:ROIV

$36.91 -0.61 (-1.63%)

Closing price 04:00 PM Eastern

Extended Trading

$33.94 -2.97 (-8.04%)

As of 07:55 PM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CYTK, ALNY, GMAB, and ROIV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CYTK, ALNY, GMAB, and ROIV Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CYTK, ALNY, GMAB, and ROIV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYTK, ALNY, GMAB, and ROIV Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Cytokinetics NASDAQ:CYTK

Genmab A/S NASDAQ:GMAB

Roivant Sciences NASDAQ:ROIV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CYTK, ALNY, GMAB, and ROIV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CYTK, ALNY, GMAB, and ROIV Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CYTK, ALNY, GMAB, and ROIV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYTK, ALNY, GMAB, and ROIV Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Cytokinetics NASDAQ:CYTK

Genmab A/S NASDAQ:GMAB

Roivant Sciences NASDAQ:ROIV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools